Tacrolimus’ original drug was developed by Fujisawa Pharmaceutical, which became Astellas after the merger. Tacrolimus was launched in China in 2005. In addition to Astellas, other manufacturers in the Chinese Tacrolimus market are Hangzhou Zhongmeihuadong, LEO, Zhejiang Hisun, and Sinopharm Chuankang.
According to this market research, the sales value of Tacrolimus in China has an increasing trend from 2016 to 2020, with a CAGR of approximately 13.5% from 2016 to 2020. The sales revenue of Tacrolimus in China was CNY1.57 billion in 2020. The growth rate in 2020 was 4.8% Year on Year, which slowed down compared to that in the previous years due to the COVID-19 epidemic.
The analyst analyzes that as the epidemic situation has been improved and the hospitals resume their operation, sales of Tacrolimus will have a recovery growth from 2021 to 2025. Besides, sales will also increase due to market expansion. In light of research findings, the indication for preventing rejection in transplantation operations generates the most sales for Tacrolimus. However, the number of new dialysis patients each year far exceeds the number of organ transplant operations, which means the demand for transplantation is not satisfied. With the development of policies and the increase in the number of organ donations, more patients will be able to receive transplants in the future, which will increase the demand for Tacrolimus.
Topics Covered:
- The impact of COVID-19 on China's Tacrolimus market
- Sales value and volume of China's Tacrolimus 2016-2020
- Competitive landscape of China's Tacrolimus market
- Prices of Tacrolimus in China
- Prices of Tacrolimus in China by regions and manufacturers
- Analysis of factors affecting the development of China's Tacrolimus market
- Prospect of China's Tacrolimus market from 2021 to 2025
Table of Contents
Samples
LOADING...
Companies Mentioned
- Astellas Pharma Co Ltd
- Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.
- LEO Pharma A/S
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Sinopharm Chuankang Pharmaceutical Co., Ltd.
Methodology
Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.
Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.
Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.
The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.
The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.
1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.
LOADING...
Table Information
Report Attribute | Details |
---|---|
Published | April 2021 |
Forecast Period | 2016 - 2025 |
Estimated Market Value ( CNY | CNY 950 Million |
Forecasted Market Value ( CNY | CNY 2533 Million |
Compound Annual Growth Rate | 11.5% |
Regions Covered | China |
No. of Companies Mentioned | 5 |